在肺移植接受者中优化莱涅佐利德剂量:人口药理动力学,目标实现和血小板缩风险评估
Dan Zhang1, Wenwen Du1, Pengmei Li1
1Department of Pharmacy, China-Japan Friendship Hospital, Beijing, China.
Journal of clinical pharmacology
|February 5, 2026
概括
对于肺移植接受者 (LTRs) 的莱涅佐利德剂量需要调整. 一种种群的药理动力学模型有助于优化治疗方案,考虑功能和塔克罗利斯水平,以降低血小板缺血风险.
科学领域:
- 药理学 药理学是指药理学的学科.
- 移植医学 移植医学
- 传染性疾病 传染性疾病
背景情况:
- 在肺移植接受者 (LTRs) 中,莱涅佐利德的药理动力学 (PK) 概况有所不同.
- 优化linezolid剂量对于LTRs的疗效和安全至关重要.
- 血小板缺血是linezolid的潜在副作用之一.
研究的目的:
- 在LTRs中开发linezolid的种群药理动力学 (PopPK) 模型.
- 评估不同的linezolid剂量方案.
- 评估与linezolid治疗相关的血小板缺血的风险.
主要方法:
- 使用非线性混合效应建模来构建PopPK模型.
- 蒙特卡洛模拟评估了目标实现的概率 (PTA).
- 分析了来自43个LTR的数据,其中有142个linezolid度-时间点.
主要成果:
- 估计的膜过率和塔克罗利斯的最低水平被确定为线索利德清除的关键共变量.
- 每日两次300毫克的治疗方案维持了治疗度.
- 每天服用600毫克的疗法实现了>80%的PTA,MIC高达1毫克/升.
- 利尼佐利德Cmin和基线血小板水平影响了血小板缺血症的严重程度.
结论:
- 开发的PopPK模型为优化LTRs中的linezolid剂量提供了基础.
- 建议根据功能和同时服用免疫抑制剂进行剂量调整.
- 该模型有助于平衡线索利德的疗效和LTRs中的血小板缺血风险.
相关概念视频
Analysis of Population Pharmacokinetic Data
758
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
758
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
689
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
A study on guinea pigs examined the...
689
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
281
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
281
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
247
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
247
Conservation of Small Populations
17.4K
Small population sizes put a species at extreme risk of extinction due to a lack of variation, and a consequent decrease in adaptability. This weakens the chances of survival under pressures such as climate change, competition from other species, or new diseases. Large populations are more likely to survive pressures such as these, as such populations are more likely to harbor individuals that have genetic variants that are adaptive under new stresses. Small populations are much less...
17.4K
Optimal Foraging
13.9K
How animals obtain and eat their food is called foraging behavior. Foraging can include searching for plants and hunting for prey and depends on the species and environment.
13.9K


